Internal Server Error

Arzeda - About the company

Arzeda is a series B company based in Seattle (United States), founded in 2008 by Alexandre Zanghellini, David Baker and Daniela Grabs-Rothlisberger. It operates as a Developer of enzyme design technology to bridge the gap by creating synthetic enzymes. Arzeda has raised $95.2M in funding from OS Fund and Conti Ventures. The company has 171 active competitors, including 30 funded and 25 that have exited. Its top competitors include companies like Nautilus Biotechnology, Somalogic and Biognosys.

Company Details

Developer of enzyme design technology to bridge the gap by creating synthetic enzymes. The proprietary technology combines targeted computational enzyme design and protein optimization with metabolic bioengineering to create entirely novel designer cell factories capable of industry-scale chemical production.
Social
X
Registered Address
Seattle, Washington
Key Metrics
Founded Year
2008
Location
Seattle, United States
Stage
Series B
Total Funding
$95.2M in 25 rounds
Latest Funding Round
Investors
Ranked
Employee Count
79 as on Aug 31, 2026
Similar Companies
Sign up to download Arzeda's company profile

Arzeda's funding and investors

Arzeda has raised a total funding of $95.2M over 25 rounds. Arzeda has 24 institutional investors.

Here is the list of recent funding rounds of Arzeda:lockFilter this list
Date of Funding
Funding Amount
Round Name
Post-Money Valuation
Revenue Multiple
Lead Investors
Other Investors
Aug 28, 2025
2046161
Series B
4478208
4814997
2175152
2322690
May 28, 2025
8414717
Grant (prize money)
2185439
6798452
1637865
Apr 08, 2025
8801402
Grant (prize money)
2413793
4934657
5032764
lockAccess funding benchmarks and valuations. Sign up today!

Arzeda's founders and board of directors

Founder? Claim Profile
The founders of Arzeda are Alexandre Zanghellini, David Baker and Daniela Grabs-Rothlisberger. Alexandre Zanghellini is the CEO of Arzeda.
Here are the details of Arzeda's key team members:

Arzeda's Board of Directors

Arzeda's board has 14 active members. Larry Page, Doug Cameron, Alexandre Zanghellini, Sanjay Pal, Brian Loeb, Jeff Klunzinger, Nanda Kumar R Puthucode, Daniela Grabs, William Baum, Jeffrey Klunzinger, Bill Baum, Andrew Ban, Eric Althoff and Yanniv Dorone are independent board members.
Here is the list of Arzeda's board of directors:
Name
Type
Representing
Status
Duration
Independent board member
-
Current
2y 9m
tmgvill
Independent board member
-
Current
3y 6m
lqgsyng
Independent board member
-
Current
8y 1m
xxfuuht
Independent board member
-
Current
8y 1m
fflabap
Independent board member
-
Current
7y 2m
dlsflwt
Independent board member
-
Current
6y 2m
{izptaw
Independent board member
-
Current
7y 4m
spflxoh
Independent board member
-
Current
2y 4m
amxefrm
Independent board member
-
Current
5y 5m
joyemkr
Independent board member
-
Current
4y 3m
igwikmm
Independent board member
-
Current
5y 8m
fjysupj
Independent board member
-
Current
6y 1m
bgctuue
Independent board member
-
Current
6y 9m
yfbuqxk
Independent board member
-
Current
1y 4m

Arzeda's employee count trend

Arzeda has 79 employees as of Aug 26. Here is Arzeda's employee count trend over the years:
Employee count trend for Arzeda
lockUncover Arzeda's growth story! Sign up today!
chrome_extension_cta_illustration
Access Tracxn on any website
Our Google Chrome extension lets you view company details while browsing their websites
Install Tracxn Extension

Arzeda's Competitors and alternates

Top competitors of Arzeda include Nautilus Biotechnology, Somalogic and Biognosys. Here is the list of Top 10 competitors of Arzeda, ranked by Tracxn score:
Rank
Company Details
Short Description
Total Funding
Investors
Tracxn Score
1st
Logo for Nautilus Biotechnology
Nautilus Biotechnology
2016, Seattle (United States), Public
Developer of proteomics platform for drug development
$453M
65/100
2nd
Logo for Somalogic
Somalogic
1999, Boulder (United States), Acquired
Developer of protein-based assays for life science research
$664M
64/100
3rd
Logo for Biognosys
Biognosys
2008, Schlieren (Switzerland), Acquired
Provider of proteomics service
$9.13M
63/100
4th
Logo for Arzeda
Arzeda
2008, Seattle (United States), Series B
Developer of enzyme design technology to bridge the gap by creating synthetic enzymes
$95.2M
59/100
5th
Logo for A-Alpha Bio
A-Alpha Bio
2017, Seattle (United States), Series A
Developer of cell-based tool for the measurements of protein interactions
$45.2M
57/100
6th
Logo for Mursla
Mursla
2017, London (United Kingdom), Seed
Provider of diagnostic device for cancer detection
$547K
55/100
7th
Logo for ProteinSimple
ProteinSimple
2004, San Jose (United States), Acquired
Provider tools to help researchers with protein analysis
$94.3M
54/100
8th
Logo for Amunix
Amunix
2006, Mountain View (United States), Acquired
Developer of peptide-based therapeutics
$201M
49/100
9th
Logo for Dynamic Biosensors
Dynamic Biosensors
2011, Planegg (Germany), Acquired
Provides solutions for label-free molecular interaction and biophysical analysis
$5.83M
49/100
10th
Logo for Akonni
Akonni
2003, Frederick (United States), Series C
Molecular diagnostics and sample prep solutions for high-quality nucleic acid purification
$39.7M
49/100
lockGet insights and benchmarks for competitors of 2M+ companies! Sign up today!
Looking for more details on Arzeda's competitors? Click here to see the top ones

Arzeda's Investments and acquisitions

Arzeda has made no investments or acquisitions yet.

Reports related to Arzeda

Here is the latest report on Arzeda's sector:

News related to Arzeda

lockFilter this list
Media has covered Arzeda for a total of 6 events in the last 1 year, 2 of them have been about partnerships and 1 about company updates.
•
Arzeda Files Notice to Raise $25 Million in New Fundingintelligence360•Sep 29, 2025•Arzeda
lockGet curated news about company updates, funding rounds, M&A deals and others. Sign up today!

FAQs about Arzeda

Explore our recently published companies
Tracxn powers 1,000+ customers across 30+ countries
Accel PartnersPartechIN-Q-TEL - USFujitsuTenityStanford